Special Issue

Multiple Organ Dysfunctions in Perioperative or ICU Critical Illnesses

Message from the Guest Editor

Multiorgan dysfunction has a high incidence in perioperative or ICU critical illnesses. Critical illness has a significantly worse prognosis after ICU or perioperative multiorgan dysfunction. This is a major challenge for global health care. There are limited effective treatment options for organ dysfunction in perioperative or ICU critical illnesses, mainly owing to its unclear pathogenesis and the lack of early-warning biomarkers and early-monitoring tools and interventions. With this Special Issue, we aim to collect data on the mechanisms, early-warning biomarkers. early-monitoring tools and interventions relating to organ dysfunction in perioperative or ICU critical diseases. Authors are welcome to submit reviews, original research and other article types on the following themes: 1. The mechanisms of multiorgan dysfunction in critical disease, such as oxidative stress, inflammatory response, etc.; 2. Early biomarkers for organ dysfunction in critical disease; 3. Monitoring or evaluation measures for organ dysfunction in perioperative or ICU critical disease; 4. Precision treatment strategies for organs undergoing critical diseases.

Guest Editor

Prof. Dr. Keliang Xie

1. Department of Critical Care Medicine and Anesthesiology, Tianjin Medical University General Hospital, Tianjin, China

2. Institute of Anesthesiology, Tianjin, China

Deadline for manuscript submissions

closed (20 March 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/139484

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

